These amino acid substitutions in core region of different HCV genotypes are associated with increased HCC risk[13-17], variable responses to IFN/RBV therapy[18-24], liver steatosis[27-30] and IR[12]. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.